Alkermes ( ($ALKS) ) has shared an announcement. On November 18, 2025, Alkermes plc and Avadel Pharmaceuticals plc amended their transaction agreem......

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Alkerme......

Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes today and set a price target of $58.00. Tewari covers the Healthcare sector, foc......

RBC Capital analyst Leonid Timashev maintained a Buy rating on Alkermes on November 10 and set a price target of $47.00. The company’s shares close......

Roth MKM analyst initiated coverage with a Buy rating on Alkermes yesterday and set a price target of $50.00. In addition to Roth MKM, Alkermes als......

In a report released yesterday, Joon Lee from Truist Financial initiated coverage with a Buy rating on Alkermes and a price target of $50.00. The c......

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes, with a price target of $42.00. Matteis covers th......

In a report released on October 28, Leonid Timashev from RBC Capital maintained a Buy rating on Alkermes, with a price target of $47.00. The compan......

Alkermes plc ( ($ALKS) ) has released its Q3 earnings. Here is a breakdown of the information Alkermes plc presented to its investors. Alkermes plc......